Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study.

Hum Brain Mapp. 2018 Oct 19. doi: 10.1002/hbm.24401. [Epub ahead of print]

PMID:
30368979
2.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
3.

Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.

Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative* and the PREVENT-AD Research Group.

Brain. 2018 Jun 1;141(6):1871-1883. doi: 10.1093/brain/awy093.

4.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

PMID:
29482212
5.

White Matter Structure in Older Adults Moderates the Benefit of Sleep Spindles on Motor Memory Consolidation.

Mander BA, Zhu AH, Lindquist JR, Villeneuve S, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP.

J Neurosci. 2017 Nov 29;37(48):11675-11687. doi: 10.1523/JNEUROSCI.3033-16.2017. Epub 2017 Oct 30.

6.

Highly efficient solid phase supported radiosynthesis of [11 C]PiB using tC18 cartridge as a "3-in-1" production entity.

Boudjemeline M, Hopewell R, Rochon PL, Jolly D, Hammami I, Villeneuve S, Kostikov A.

J Labelled Comp Radiopharm. 2017 Dec;60(14):632-638. doi: 10.1002/jlcr.3569. Epub 2017 Nov 30.

PMID:
28981146
7.

Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load.

Grothe MJ, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2017 Feb 7;88(6):569-576. doi: 10.1212/WNL.0000000000003585. Epub 2017 Jan 6.

8.

Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.

Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, DeCarli C, Miller BL, Rosen HJ, Boxer AL, O'Neil JP, Jin LW, Seeley WW, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2016 Nov 11;13:130-137. eCollection 2017.

9.

Cause of Suspected Non-Alzheimer Disease Pathophysiology: If Not Tau Pathology, Then What?

Villeneuve S.

JAMA Neurol. 2016 Oct 1;73(10):1177-1179. doi: 10.1001/jamaneurol.2016.2842. No abstract available.

PMID:
27548079
10.

β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals.

Fletcher E, Villeneuve S, Maillard P, Harvey D, Reed B, Jagust W, DeCarli C.

Neurobiol Aging. 2016 Apr;40:173-180. doi: 10.1016/j.neurobiolaging.2016.01.133. Epub 2016 Feb 22.

11.

Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality.

Villeneuve S, Brisson D, Gaudet D.

J Lipids. 2015;2015:742408. doi: 10.1155/2015/742408. Epub 2015 Oct 28.

12.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.

13.

Are AD-Typical Regions the Convergence Point of Multiple Pathologies?

Villeneuve S, Wirth M, La Joie R.

Front Aging Neurosci. 2015 Mar 25;7:42. doi: 10.3389/fnagi.2015.00042. eCollection 2015. Review. No abstract available.

14.

Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Villeneuve S, Jagust WJ.

J Prev Alzheimers Dis. 2015 Mar;2(1):64-70.

15.

The potential applications of Apolipoprotein E in personalized medicine.

Villeneuve S, Brisson D, Marchant NL, Gaudet D.

Front Aging Neurosci. 2014 Jul 8;6:154. doi: 10.3389/fnagi.2014.00154. eCollection 2014. Review.

16.

Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden.

Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ.

J Neurosci. 2014 Jun 18;34(25):8612-7. doi: 10.1523/JNEUROSCI.4612-13.2014.

17.

Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions.

Villeneuve S, Reed BR, Madison CM, Wirth M, Marchant NL, Kriger S, Mack WJ, Sanossian N, DeCarli C, Chui HC, Weiner MW, Jagust WJ.

Neurology. 2014 Jul 1;83(1):40-7. doi: 10.1212/WNL.0000000000000550. Epub 2014 Jun 6.

18.

Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults.

Wirth M, Haase CM, Villeneuve S, Vogel J, Jagust WJ.

Neurobiol Aging. 2014 Aug;35(8):1873-82. doi: 10.1016/j.neurobiolaging.2014.02.015. Epub 2014 Feb 20.

19.

Cortical thickness mediates the effect of β-amyloid on episodic memory.

Villeneuve S, Reed BR, Wirth M, Haase CM, Madison CM, Ayakta N, Mack W, Mungas D, Chui HC, DeCarli C, Weiner MW, Jagust WJ.

Neurology. 2014 Mar 4;82(9):761-7. doi: 10.1212/WNL.0000000000000170. Epub 2014 Jan 31.

20.

Associations between serum cholesterol levels and cerebral amyloidosis.

Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W.

JAMA Neurol. 2014 Feb;71(2):195-200. doi: 10.1001/jamaneurol.2013.5390.

Supplemental Content

Loading ...
Support Center